These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac. Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J; Kosteiny SA; Gansow OA; Nelson DL Cancer Res; 1994 Aug; 54(16):4362-70. PubMed ID: 8044783 [TBL] [Abstract][Full Text] [Related]
7. Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclides (212)Bi or (211)At. Wesley JN; McGee EC; Garmestani K; Brechbiel MW; Yordanov AT; Wu C; Gansow OA; Eckelman WC; Bacher JD; Flynn M; Goldman CK; MacLin M; Schwartz UP; Jackson-White T; Phillip CM; Decker J; Waldmann TA Nucl Med Biol; 2004 Apr; 31(3):357-64. PubMed ID: 15028248 [TBL] [Abstract][Full Text] [Related]
8. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Junghans RP; Waldmann TA; Landolfi NF; Avdalovic NM; Schneider WP; Queen C Cancer Res; 1990 Mar; 50(5):1495-502. PubMed ID: 2406013 [TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of anti-IL-2R monoclonal antibodies. ART-18 prolongs cardiac allograft survival in rats by elimination of IL-2R+ mononuclear cells. Tanaka K; Hancock WW; Osawa H; Stunkel KG; Alberghini TV; Diamantstein T; Tilney NL; Kupiec-Weglinski JW J Immunol; 1989 Nov; 143(9):2873-9. PubMed ID: 2530281 [TBL] [Abstract][Full Text] [Related]
10. Anti-CD25 monoclonal antibody modulates cytokine expression and prolongs allografts survival in rats cardiac transplantation. Xia J; Jiang X; Huang Y; Zhang K; Xiao S; Yang C Chin Med J (Engl); 2003 Mar; 116(3):432-5. PubMed ID: 12781053 [TBL] [Abstract][Full Text] [Related]
11. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. Hakimi J; Chizzonite R; Luke DR; Familletti PC; Bailon P; Kondas JA; Pilson RS; Lin P; Weber DV; Spence C J Immunol; 1991 Aug; 147(4):1352-9. PubMed ID: 1869828 [TBL] [Abstract][Full Text] [Related]
12. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Anasetti C; Hansen JA; Waldmann TA; Appelbaum FR; Davis J; Deeg HJ; Doney K; Martin PJ; Nash R; Storb R Blood; 1994 Aug; 84(4):1320-7. PubMed ID: 8049447 [TBL] [Abstract][Full Text] [Related]
13. Anti-IL-2 receptor monoclonal antibody (anti-Tac) treatment of T-cell lymphoma. Waldmann TA Important Adv Oncol; 1994; ():131-41. PubMed ID: 8206486 [TBL] [Abstract][Full Text] [Related]
14. Prolongation of primate cardiac allograft survival by treatment with ANTI-CD40 ligand (CD154) antibody. Pierson RN; Chang AC; Blum MG; Blair KS; Scott MA; Atkinson JB; Collins BJ; Zhang JP; Thomas DW; Burkly LC; Miller GG Transplantation; 1999 Dec; 68(11):1800-5. PubMed ID: 10609959 [TBL] [Abstract][Full Text] [Related]
16. The role of a primate model of renal transplantation in the development of new monoclonal antibodies. Shapiro ME; Reed MH; Strom TB; Carpenter CB; Milford EL; Kirkman RL Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):58-60. PubMed ID: 2816938 [TBL] [Abstract][Full Text] [Related]
18. Identification of IL 2R+ T cells and macrophages within rejecting rat cardiac allografts, and comparison of the effects of treatment with anti-IL 2R monoclonal antibody or cyclosporin. Hancock WW; Lord RH; Colby AJ; Diamantstein T; Rickles FR; Dijkstra C; Hogg N; Tilney NL J Immunol; 1987 Jan; 138(1):164-70. PubMed ID: 3097143 [TBL] [Abstract][Full Text] [Related]
19. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status. Swiatecka-Urban A Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627 [TBL] [Abstract][Full Text] [Related]
20. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction. Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]